Pharmacogenetics and obesity: Common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects

Pharmacogenetics and Genomics

Volumn 15, Issue 12, 2005, Pages 883-889

  Spraggs, Colin F ^a   Pillai, Sreekumar G ^b   Dow, David ^b   Douglas, Christal ^b   McCarthy, Linda ^b   Manasco, Penelope K ^b   Stubbins, Michael ^b   Roses, Allen D ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NONE

Author keywords

GRIN1; Neuronal re uptake inhibitors; SLC6A2; Weight loss efficacy

Indexed keywords

DOPAMINE UPTAKE INHIBITOR; MANIFAXINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEADACHE; HUMAN; HYPOSALIVATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OBESITY; PAIN; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; WEIGHT REDUCTION;

EID: 27944439330     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: 10.1097/01213011-200512000-00006     Document Type: Article

References (29)

1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001; 7:201-203.
2. Feature. Genetic variation in drug development. Nat Biotech 1998; 16:16-19.
3. Gennis MA, Vemuri R, Burns EA, Hill JV, Miller MA, Speilberg S. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91:631-634.
4. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic response in asthma. Br Med Bull 2000; 56:1054-1070.
5. Kuivenhoven JA, Jukema JW, Zwinderman AH, deKnijff P, McPherson R, Brushke AVG, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Eng J Med 1998; 338:86-93.
6. Arranz M, Collier D, Sodhi M, Ball D, Roberts GW, Sham P, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346:281-282.
7. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168-170.
8. Roses AD. Genome-based pharmacogenetics and the pharmaceutical industry. Nat Rev: Drug Discovery 2002; 1:541-549.
9. Glazer G. Long term pharmacotherapy of obesity: a review of efficacy and safety. Arch Intern Med 2001; 161:1814-1824.
10. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56:1093-1124.
11. Lean ME. Sibutramine: a review of clinical efficacy. Int J Obesity Rel Metab Dis 1997; 21:S30-S36.
12. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286:1331-1339.
13. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000; 356:2119-2125.
14. Hauner H, Meier M, Jockel KH, Frey UH, Siffert W. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13:453-459.
15. Sahelijo L, Katz DA, Spear BB. Prediction of successful weight reduction under sibutramine therapy. Pharmacogenetics 2004; 14:387-389.
16. DeVeaugh-Geiss J, Conners CK, Sarkis EH, Winner PK, Ginsberg LD, Hemphill MJ, et al. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. J Am Acad Child Adolesc Psychiatry 2002; 41:914-920.
17. Zaykin D, Zhivotovsky L, Weir BS. Exact tests for association between alleles at arbitrary numbers of loci. Genetica 1995; 96:169-178.
18. Weir BS. Genetic Data Analysis II, 1996. Sinauer Associated, Inc. Publishers, Sunderland, Massachusetts.
19. Costello TJ, Swartz MD, Sabripour M, Gu X, Sharma R, Etzel CJ. Use of tree-based models to identify subgroups and increase power to detect linkage to cardiovascular disease traits. BMC Genet 2003; 4(suppl 1):S66.
20. Shannon WD, Province MA, Rao DC. Tree-based recursive partitioning methods for subdividing sibpairs into relatively more homogeneous subgroups. Genet Epidemiol 2001; 20:293-306.
21. Wilcox MA, Smoller JW, Lunetta KL. Using recursive partitioning for exploration and follow-up of linkage and association analyses. Genet Epidemiol 1999; 17(suppl 1):S391-S396.
22. Meyer J, Weidermann P, Okladnova O, Bruss M, Staab G, Stober G, et al. Cloning and functional characterization of the human norepinephrine transporter gene promoter: Rapid Communication. J Neural Transm 1999; 105:1341-1350.
23. Stober G, Nothen M, Porzgen P, Bruss M, Bonisch H, Knapp M, et al. Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders. Am J Med Genet 1996; 67:523-532.
24. Shannon JR, Flatten NL, Jordan J, Jacob G, Black BK, Biaggioni I, et al. Orthostatic intolerance and tachycardia associated with norepinephrine transporter deficiency. N Engl J Med 2000; 342:541-549.
25. Paczkowski FA, Bonisch H, Bryan-Lluka L, Lesley J. Pharmacological properties of the naturally occurring Ala457Pro variant in the human norepinephrine transporter. Pharmacogenetics 2000; 12:165-173.
26. Winsberg BJ, Coming DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999; 38:1474-1477.
27. Heinz A, Goldman D, Jones DW, Palmour R, Hommer D, Gorey CNMT, et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 2000; 22:133-139.
28. Shanley I, Irving A, Harvey J. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci 2001; 21:1-6.
29. Okabe S, Miwa A, Okadu H. Alternative splicing of the C terminal domain regulates cell surface expression of the NMDA receptor NR1 subunit. J Neurosci 1999; 19:7781-7792.